Skip to main content
Pharmala Biotech Holdings Inc. logo

Pharmala Biotech Holdings Inc. — Investor Relations & Filings

Ticker · MDMA ISIN · CA71719L1067 CSE Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing CSE MDMA

About Pharmala Biotech Holdings Inc.

https://pharmala.ca/

Pharmala Biotech Holdings Inc. is a biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and novel MDXX class molecules. The company produces LaNeo™ MDMA, an Active Pharmaceutical Ingredient (API) manufactured under Good Manufacturing Practice (GMP) standards, intended for the scientific research community and commercial clinical use in authorized jurisdictions. Pharmala's strategy emphasizes a "regulatory-first" approach, including preclinical research and development of Novel Chemical Entities (NCEs) based on MDXX analogs to enhance safety profiles. The company has established the first legal commercial value chain in North America for GMP LaNeo™ MDMA products and is a primary supplier of MDMA for human use manufactured under GMP guidelines.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 90% confidence The document is a Form 51-102F3 Material Change Report filed on SEDAR+ by a Canadian issuer. It outlines material contract and joint‐venture/license agreements and discloses corporate transaction details per NI 51-102. It is not a full annual or interim report, nor an earnings release or proxy material. It is a regulatory compliance filing announcing material corporate changes. Therefore, the correct classification is a general regulatory filing (RNS).
2026-05-22 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release announcing a non‐debt, equity and cash‐based licensing deal (term sheet) valued at over $100 million, including upfront payments, milestone payments, royalties, share consideration, and escrow arrangements. This constitutes a financing/transaction update rather than a full financial report, merger, dividend, or other category. Therefore it best fits Capital/Financing Update (CAP).
2026-05-20 English
Other material contracts - English.pdf
Regulatory Filings Classification · 80% confidence The document is a private SPV formation, shareholder and license agreement — a corporate contract outlining formation of a special purpose vehicle, share issuance, licensing terms and related governance mechanisms. It contains no financial statements, earnings data, regulatory certifications, proxy materials, dividends notices, or other standard reporting elements. It is neither an Annual Report, Interim Report, Management Discussion & Analysis, proxy statement, nor any financing or M&A announcement covered by the defined categories. Therefore it falls into the fallback category of general regulatory or miscellaneous filings (RNS).
2026-05-14 English
News release - English.pdf
Regulatory Filings
2026-05-13 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings
2026-05-12 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2026-05-01 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.